Health insurance doesn't always cover GLP-1 medications when they're prescribed for weight loss
Europe: The Second-Largest Market Europe held the second-largest share of 23% in 2025 and is expected to grow at a notable CAGR of 13.1% during the projection period, driven mainly by expanding reimbursement and treatment access
Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ
Because they're classed as food supplements rather than medicines, they don't go through the same rigorous clinical testing, safety reviews, or approval processes that prescription treatments like Mounjaro and Wegovy do
GLP-1 RAs reduce cardiovascular risks but may cause nausea and GI issues
In addition to antidiabetic medications, some may also be prescribed by medical professionals for the treatment and management of obesity